Keith Fortier, MD in Waterford, VT - Obstetrics & Gynecology

Keith Fortier, MD is a Obstetrics & Gynecology physician based in Waterford, Vermont. Keith Fortier is licensed to practice in Vermont (license number 042-0006155) and his current practice location is 594 Copenhagen Rd, Waterford, Vermont. He can be reached at his office (for appointments etc.) via phone at (802) 748-8573.

NPI number for Keith Fortier is 1740390053 and his current mailing address is 594 Copenhagen Rd, Waterford, Vermont. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1740390053.

Contact Information

	Keith Fortier, MD
	594 Copenhagen Rd, Waterford, VT 05819-9055
	(802) 748-8573
	(707) 734-8573

Physician's Profile

Full Name	Keith Fortier
Gender	Male
Speciality	Obstetrics & Gynecology
Location	594 Copenhagen Rd, Waterford, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1740390053
Provider Enumeration Date: 08/30/2006
Last Update Date: 01/28/2010

Medical Identifiers

Medical identifiers for Keith Fortier such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740390053	NPI	-	NPPES
0007981	Medicaid	VT

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207V00000X	Obstetrics & Gynecology	042-0006155 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Keith Fortier is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Keith Fortier, MD 594 Copenhagen Rd, Waterford, VT 05819-9055 Ph: (802) 748-8573	Keith Fortier, MD 594 Copenhagen Rd, Waterford, VT 05819-9055 Ph: (802) 748-8573

News Archive

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

Metabolic syndrome risk for veterans with post-traumatic stress disorder

Veterans with post-traumatic stress disorder (PTSD) are more likely to have metabolic syndrome than veterans without PTSD.

Methamphetamine, biggest illegal drug menace in America

Ten Attorneys General and officials from 13 other states came together today to attack what they called the biggest illegal drug menace in America: the use and production of methamphetamine.

Adding evidence-based weight loss strategies enhances statewide wellness campaign

Researchers from The Miriam Hospital have found that adding evidence-based weight loss strategies to a statewide wellness campaign improves weight loss outcomes among participants. The study and its findings are published online in advance of print in the American Journal of Public Health.

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.

Keith Fortier, MD - Obstetrics & Gynecology in Waterford, VT